PitchSend

Investor Presentaiton

Summary and Conclusions - - Daprodustat was as effective as conventional ESA therapy in treating anemia of CKD Daprodustat was noninferior to ESA with respect to CV safety and no new safety signals were observed Daprodustat could represent an oral alternative to ESA for treating anemia of CKD in both dialysis and non-dialysis patients 19 AE, adverse events; CKD, chronic kidney disease; CV, cardiovascular; MACE, major adverse cardiovascular event

View entire presentation